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Background: Von Hippel-Lindau disease is an autosomal dominantly inherited highly penetrant tumor syndrome
predisposing to retinal and central nervous system hemangioblastomas, renal cell carcinoma and
phaeochromocytoma among other less frequent complications.
Methods: Molecular genetic testing of the VHL gene was performed in five unrelated families affetced with type I
VHL disease, including seven patients and their available family members.
Results: Molecular genetic investigations detected three novel (c.163 G > T, c.232A > T and c.555C > A causing p.
Glu55X, p.Asn78Tyr and p.Tyr185X protein changes, respectively) and two previously described (c.340 + 1 G > A and
c.583C > T, resulting in p.Gly114AspfsX6 and p.195GlnX protein changes, respectively) germline point mutations in
the VHL gene. Molecular modeling of the VHL-ElonginC-HIF-1alpha complex predicted that the p.Asn78Tyr amino
acid exchange remarkably alters the 77-83 loop structure of VHL protein and destabilizes the VHL-HIF-1alpha
complex suggesting that the mutation causes type I phenotype and has high risk to associate to renal cell
carcinoma. The novel p.55X nonsense mutation associated to bilateral RCC and retinal angioma in a 15-year-old
male patient.
Conclusion: We describe the earliest onset renal cell carcinoma in VHL disease reported so far in a 15-year-old boy
with a nonsense VHL mutation. Individual tailoring of screening schedule based on molecular genetic status should
be considered in order to diagnose serious complications as early as possible. Our observations add to the
understanding of genotype-phenotype correlation in VHL disease and can be useful for genetic counseling and
follow-up of VHL patients.
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Von Hippel-Lindau (VHL) disease is an autosomal dom-
inantly inherited highly penetrant tumor syndrome
affecting 1 in 36,000 individuals worldwide. VHL disease
predisposes to retinal and central nervous system heman-
gioblastomas (HB), renal cell carcinoma (RCC), phaeochro-
mocytoma, pancreatic endocrine tumors, endolymphatic* Correspondence: losigeri@gmail.com
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reproduction in any medium, provided the orsac tumors among other less frequent complications. Type
1 diseases is accompanied with low risk of phaeochromocy-
toma, type IIa is associated with high risk of phaeochromo-
cytoma and low risk of renal cell carcinoma, while type IIb
is linked to high risk of both phaeochromocytoma and
renal cell carcinoma. In type IIc VHL disease only phaeo-
chromocytoma develops. Patients carry a heterozygous
germline mutation in the VHL gene. Tumor development
is initiated by the somatic inactivation or loss of the
remaining wild type VHL allele [1,2]. VHL protein associ-
ates with the elongins B and C, cullin2 and Rbx andal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ubiquitin ligase that ubiquitinates HIF-1aplha under nor-
moxic conditions resulting in HIF-1alpha proteolysis [3].
The protein model of pVHL19 contains two functional
subdomains; the beta domain (residues 63–154 and resi-
dues 193–204) and the helical alpha-domain (residues
155–192). Two important binding sites within VHL pro-
tein have been identified; one responsible for elongin C
binding in the alpha domain (amino acid residues 157–
170) and the other in the beta domain responsible for
the binding of HIF1alpha (amino acid residues 91–113)
[4]. The majority of disease-causing missense VHL gene
mutations are located in one of these two binding sites.
Molecular genetic defects identified in the background
of the disease have greatly helped to understand the role
of VHL protein in the hypoxia sensing pathway and to
recognize genotype-phenotype correlation, a prerequisite
of efficient genetic counseling and patient follow-up [5].
More than 800 different germline mutations are listed in
the VHL mutation database (http://www.umd.be:2020/)
[6] and also in a comprehensive analysis based on 945
VHL kindreds [7]. Here, we describe 7 members of 5
families with three novel and one previously reported
point mutations in the VHL gene and correlate genetic
findings with clinical phenotype.
Methods
Patients
Seven members of five unrelated Hungarian families
with von Hippel-Lindau disease were investigated at the
Division of Rare Diseases and the Department of Oph-
thalmology, at the University of Debrecen in Debrecen,
Hungary between 1998 and 2011. The diagnosis of VHL
disease was based on physical and ophthalmological
examinations, abdominal CT, craniospinal and abdominal
MRI and laboratory tests (routine blood tests and urine
catecholamines and vanillylmandelic acid). All examina-
tions were in line with previously reported screening pro-
tocols [2,8-10]. One hundred apparently healthy controls
were enrolled in the study. Controls, Patients and family
members were enrolled after having signed informed con-
sent. All procedures strictly adhered to the Declaration of
Helsinki. Approval was obtained from local Institutional
Ethics Committees at the University of Debrecen.
Mutation analysis of the VHL gene
Blood samples from patients and family members were
obtained after informed consent. Genomic DNA was
purified from peripheral white blood cells. Exons of the
VHL gene were amplified using the following primer
pairs: 1AF 50-TATAGTGGAAATACAGTAACGAG-30,
1AR 50-GAAGTTGAGCCATACGG-30, 1BF 50- AGAG
TACGGCCCTGAAGAA-30, 1BR 50-GCTTACGAGCA
GCGTCAC-30, 2 F 50-ATCTCCTGACCTCATGATCC-30, 2R 50- GGGCTTAATTTTTCAAGTGG-30, 3 F 50-
TGAGATCCATCAGTAGTACAGG-30, 3R 50- CTAAG
GAAGGAACCAGTCC-30. After an initial denaturation
step at 95°C for 10 minutes, 40 PCR cycles were per-
formed under the following conditions: denaturation at
95°C for 1 minute, annealing at 56°C for exon 1 and 59°C
for exons 2 and 3 for 1 minute and extension at 72°C for
1 min. An additional elongation step for 7 minutes at 72°C
followed the final cycle. PCR products purified by ultra-
filtration were sequenced by ABIPrism 3100 Genetic
Analyzer (Applied Biosystems, Foster City, CA) from both
forward and reverse primers. Clinical and genetic data of
previously reported VHL cases were obtained from cited
publications and from the Universal Mutation Database
[6]. Large deletions were tested using the Multiplex
Ligation-dependent Probe Amplification (MLPA) VHL kit
(MRC-Holland, Amsterdam, NL).
Evolutionary alignment, SIFT analysis and molecular
modeling
Multiple evolutionary protein sequence alignment was
performed using the open access source of Constraint-
based Multiple Alignment Tool (COBALT) in the case
of the p.N78Y mutation [11]. To estimate whether this
amino acid substitution affects protein function we also
applied the online available SIFT analysis tool (http://sift.
jcvi.org/). SIFT prediction is based on the degree of
conservation of amino acid residues in sequence align-
ments derived from closely related sequences, collected
through PSI-BLAST [12]. We were curious whether the
SIFT tool could find any difference in the predicted ef-
fect between type I and type II missense mutations,
therefore we analyzed all germline missense mutations
of familial VHL cases reported in the comprehensive
analysis of Nordstrom-O’Brien et al. Sixty-six mutations
in both type I and II groups were analyzed.
For molecular modeling, starting geometries for the
model complexes of VHL-, Elongin C- and HIF-1α pro-
teins [13] were obtained from the RCSB protein data bank
(pdb ID: 1LM8). The unresolved N- and C-terminal frag-
ments were substituted by acetyl and N-methyl groups on
the available protein fragments then the missing hydrogen
atoms were added. Molecular dynamics simulations using
periodic boundary condition, explicit TIP3P water [14]
molecules, AMBER99SB [15,16] force field and additional
Na + and Cl- ions (~0.15 M ionic strength) were carried
out with both the wild- and the Asn78Tyr point mutated
VHL protein. 4 fs time step and 50 ns total time frame
was applied for the constant pressure (105 Pa), constant
temperature (310 K), and constant particle number
(68612, 68655 and 68548 for the wild and p.Asn78Tyr
mutant systems, respectively) simulations. The long range
electrostatics forces were calculated by particle mesh
Ewald method [17]. The simulations and the analyses of
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[18] suites of software.Results
Molecular genetic analysis of 11 members of 5 unrelated
VHL families detected 3 novel and 2 previously described
point mutations in the VHL gene. No alterations could be
detected in the VHL gene with the MLPA test. All
mutations associated to type I VHL disease. None of the
mutations could be observed in one hundred control
subjects. Phenotype characteristics and genetic data of
the study population are summarized in Table 1. Elec-
tropherograms of corresponding VHL mutations are
demonstrated in Figure 1.
Family A consisted of two healthy parents and their
15-year-old son, who developed bilateral retinal angioma
and serous retinal detachment. In search for VHL mani-
festations abdominal ultrasound scan detected a mass of
18 mm in diameter in the left kidney. Abdominal MRI
scans showed a kidney mass of 15 mm’s in the left kid-
ney and a 10 mm’s diameter mass in the right kidney. After
tumor enucleation, histological analysis verified RCC. MRI
of the craniospinal axis could not detect any alterations.
No deviation from normal values was observed in the la-
boratory test. The patient was heterozygous for the novel
c.163 G >T (p.55GluX) amber nonsense mutation. None
of his parents displayed any mutations in the VHL gene in-
dicating a de novo mutation.
Two affected probands of family B, sister (index pa-
tient, IP) and brother, with a positive family history of
VHL disease were examined. The sister developed a ret-
inal angioma of the right eye at the age of 48 years. MRI
examination revealed a cerebellar hemangioma in both
patients. RCC could not be revealed so far in any of the
patients. Molecular genetic analysis detected the novel
c.232A > T (p.Asn78Tyr) missense mutation in heterozy-
gous form in both patients.
Family C consisted of two parents and their two daugh-
ters. The 12-year-old daughter (IP) was investigated be-
cause of a retinal angioma. A spinal cord hemangiomaTable 1 Summary of clinical and genetic findings
Family Patients RCC CNS
HB
Phaeo RA VHL disease
type
ger
mu
A IP 15 - - 15 1 c.16
B IP - 48 - 48 1 c.23
Brother - 45 - 45 1 c.23
C IP 14 - 12 1 c.34
Father 34, bilateral 34 - 38 1 c.34
D IP 25 25 - - 1 c.55
E IP - 41 - 41 1 c.58
Numbers indicate patients’ age at detection of the corresponding VHL tumor. IP Ind
haemangioblastoma, Phaeo: phaeochromocytoma, RA Retinal angioma, NA Non-appwas detected on the craniospinal MRI. No other manifes-
tations of VHL disease have been detected so far in her
case. Radiological investigations detected bilateral kidney
tumors, a cerebellar and a spinal cord hemangioma in her
34-year-old father. Histological analysis of the kidney veri-
fied RCC. Four years later, retinal angioma developed in
both of his eyes. The mother and the other daughter were
free from any manifestations of the disease. Both affected
family members were heterozygous for the c.340 + 1 G >
A mutation, located at the first exon-intron junction. The
mutation destroys the conserved intronic donor splice site
and most likely leads to premature protein termination (p.
Gly114AspfsX6). The mother and the healthy daughter
showed no mutations in the VHL gene. As in our case, the
mutation associated to type I VHL phenotype in a previ-
ous report [19].
The 25-year-old male patient (Patient D) was the only
available member of the family. His father had died sev-
eral years ago due to a central nervous system tumor,
probably a complication of VHL disease. The patient was
diagnosed with cerebellar and spinal cord hemangioma
and a subsequently occurring RCC, while other manifesta-
tions of VHL disease could not be detected. The novel
heterozygous nonsense amber mutation (c.555C >A) was
detected in Patient D. The mutation caused a previously
reported protein truncation (p.185TyrX) [6,20,21].
Patient E suffered from retinal angioma and cerebellar
hemangioblastoma. No other VHL-related manifestations
could be revealed so far. Genetic analysis detected the pre-
viously described c.583C > T mutation resulting in prema-
ture protein termination (p.195GlnX). Interestingly, the
mutation has been reported to associate to type I and type
II VHL disease as well [20,22,23].SIFT analysis and evolutionary sequence alignment
The majority of missense mutations reported in the lit-
erature in familial VHL were predicted to be damaging
by SIFT analysis. However, 18% and 35% of the muta-
tions were predicted to be tolerated among mutations
associating to familial cases of type I and type II VHLmline
tation
localisation novel
mutation
Predicted protein
modification
SIFT
analysis
3 G > T exon 1 yes p.Glu55X NA
2A > T exon 1 yes p.Asn78Tyr damaging
2A > T exon 1 yes p.Asn78Tyr damaging
0 + 1 G > A intron 1-2 no p.Gly114AspfsX6 NA
0 + 1 G > A intron 1-2 no p.Gly114AspfsX6 NA
5C > A exon 3 yes p.Tyr185X NA
3C > T exon 3 no p.195GlnX NA
ex patient, RCC Clear cell renal cell carcinoma, CNS HB Central nervous system
licable.
Figure 1 Electropherograms representing VHL mutations in the study population. Mutations are indicated by arrows. Panel A: c.163 G > T,
p.Glu55X; Panel B: c.232A > T, p.Asn78Tyr; Panel C: c.340 + 1 G > A, p.Gly114AspfsX6; Panel D: c.555C > A, p.Tyr185X; Panel E: c.583C > T, p.195GlnX.
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to be noted, that the lowest rate (11%) of tolerable muta-
tions was observed in type I VHL disease associating to
RCC. As shown by Figure 2, the Asn78 amino acid
represents a highly conserved amino acid among differ-
ent species including Homo Sapiens, Pongo pygmeaus,Rattus norvegicus, Mus musculus, Canis familaris and Xen-
opus tropicalis. SIFT analysis of the current and previously
reported amino acid exchanges at this position also indi-
cated damaging effect on protein function with SIFT scores
of 0, 0, 0, 0.03 and 0.04 in case of conversion to Tyrosine,
Histidine, Isoleucin, Serine and Threonin, respectively.
Figure 2 Multiple sequence alignment of VHL protein. The Asn78 amino acid is shown in red. Asparagine amino acid in this position is
highly conserved among different species.
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Effect of the Asn78Tyr protein exchange on the molecular
structure
Molecular simulation on the model wild type VHL-
ElonginC - HIF-1alpha complex shows the protein com-
plex to be remarkably stable as it is demonstrated by the
first (Figure 3A) and last (Figure 3B) snapshots from the
corresponding trajectory. Whereas comparing the simu-
lation trajectories for the wild type and the Asn78Tyr
mutant (Figure 3C) VHL proteins it is clearly demon-
strated that this mutation remarkably deforms the 77-83
loop structure in the VHL protein. It can be interpreted
by the breaking of the loop-stabilizing H-bond inter-
action between Asn78 and and Arg82 as well as by a lar-
ger space filling property of the tyrosine side chain. This
deformation spreads over the Thr100-Arg107 loop of
VHL (marked by red arrow) which finally resulted in a
weakened interaction between this loop and the HIF-
1alpha protein (shown by green arrow). Interestingly, the
deformed loop structure in VHL deforms substantially
the neighboring loop (Arg82-Phe93) structure in ElonginFigure 3 Ribbon and balls and sticks rendering of a representative sn
Elongin C-HIF-1 alpha complexes. The ribbon model of VHL and Elongin
while the fragment of HIF-1α protein is shown in green. The first and last s
type VHL protein indicates a remarkably stable protein complex (A,B). The
the VHL protein. This deformation spreads over the Thr100-Arg107 loop of
interaction between this loop and the HIF-1alpha protein (shown by green
neighboring loop (Arg82-Phe93) structure in Elongin C (shown in blue ellip
are colored grey, blue, red and white, respectively) was used for the balls a
to play key role in interchain interactions.C (shown in blue ellipse) as well. However, this deform-
ation did not disrupt the interaction between VHL and
Elongin C in our simulation.
Discussion
We have investigated seven VHL patients from five un-
related Hungarian families. After detailed physical, oph-
thalmological, radiological and laboratory investigations
all patients were found to have type 1 VHL disease. Mo-
lecular genetic investigations detected three novel and
one previously described point mutations in the VHL
gene. According to the present and a previous report [24],
there are 12 VHL families in Hungary identified so far.
Nonsense, missense, frame shift mutations and exon dele-
tions were detected in four, four, two and two families, re-
spectively. These proportions show no major deviation
from those of other populations and are comparable to
proportions reported by the comprehensive analysis of
Nordstrom-O’Brien et al [7]. The novel c.232A > T (p.
Asn78Tyr) missense mutation associated to type I VHL
phenotype. The site is evolutionary conserved suggesting
it is an important amino acid position to maintain protein
structure and function. Other mutations at the sameapshot from molecular simulations carried out for model VHL-
C protein fragments are colored orange and purple, respectively,
napshots from the simulation trajectory of the complex including wild
Asn78Tyr mutation (C) remarkably deforms the 77-83 loop structure in
VHL (marked by red arrow) which finally results in a weakened
arrow). The deformed loop structure in VHL deforms substantially the
se in Figure 3B and Figure 3C). Atomtype coloring (C, N, O, H atoms
nd sticks model which were applied for residues which are supposed
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p.Asn78Ile associated with type I disease phenotype as
well [20,22,23,25-29]. This mutation site is buried within
the protein core where mutations were found to associate
with lower risk of phaeochromocytoma compared to pro-
tein surface missense mutations [23]. N78H, N78I and
N78S missense mutations were all reported to coincide
with RCC, however the N78T mutation did not show this
association [20,22,23,25-29]. According to a later publica-
tion RCC associates with high risk to missense mutations
located between codon 74 and 90 [30]. The effect of the
novel p.Asn78Tyr mutation on VHL protein structure was
assessed using molecular modeling. The Asn78 side chain
participates in the stabilization of the turn where it can be
found. The breaking of the loop-stabilizing H-bond inter-
action between Asn78 and Arg82 as well as the replace-
ment of this residue with a larger one obviously
destabilizes this turn (Figure 3). It can cause partial or glo-
bal misfolding. The most remarkable effect of this struc-
tural reorganization on protein interactions is the high
probability of dissociation of the VHL and HIF-1alpha pro-
teins. Despite the turn deformation, disruption of the
VHL-Elongin C interaction could not be observed during
the molecular dynamics simulation (Figure 3). In vitro ana-
lysis of pVHL mutants showed reduced ability to bind and
ubiquitinate HIF-1alpha in case of type I, IIa and IIb muta-
tions, on contrary, mutations associated to IIc phenotype
showed normal binding and ubiquitination of HIF-1alpha
protein. Completely absent HIF-1alpha binding was only
observed in consequence of mutations associating to RCC
in this study [31]. However, a recent computational study
could not confirm the dose-dependent effect of VHL-HIF-
1alpha dissociation and suggests that the canonical config-
uration of the wild-type beta domain is vital for the
efficient functioning of the complex and that mutation of
any of the residues implicated in the H-bond network in
the binding site disrupts HIF binding [32]. Taken together,
mutations in the beta domain disrupting the VHL-HIF-
1alpha interaction lead to type I disease phenotype with an
increased risk of RCC. Based on these data and our mo-
lecular modeling results we can conclude that the novel p.
Asn78Tyr mutation associates to type I disease and has a
high chance to associate to RCC as well, while only minor
risk to associate to phaeochromocytoma. In an attempt to
assess the effect of all previously reported missense muta-
tions in familial VHL, we applied SIFT analysis and found
that in type II disease the rate of tolerable mutations is sig-
nificantly higher than in type I mutations. This finding fur-
ther supports that deleterious mutations disrupting protein
integrity are more prone to cause type I phenotype. Be-
sides, it suggests that SIFT analysis can be a useful tool
when quick prediction of a novel mutation is necessary.
As expected, nonsense mutations associated with type I
VHL phenotype. Two of the three nonsense mutationsassociated to RCC as well. Previous publications show that
large germline deletions, nonsense and frameshift muta-
tions associate with type I VHL phenotype [6,20-22,25,33].
Consistent with previous publications indicating that RCC
coincides more frequently with nonsense mutations than
missense mutations, RCC only associated to MLTP in our
patients [23,34]. Nonsense mutations independent of their
exonic location associate with earlier age at onset and
higher age-related risk of RA and RCC compared to mis-
sense mutations and large deletions [23]. Supporting this
observation, the patient with the p.55GluX mutation was
15-years-old when bilateral retinal angioma and bilateral
RCC was diagnosed, which represents the earliest occur-
rence of RCC in VHL disease reported so far [1,35]. VHL
screening guidelines [2,8-10] recommend a screening
schedule for VHL patients regardless of their genetic sta-
tus in order to recognize VHL complications in a curable
stage. The earliest occurrence of RCC was reported in a
sixteen-year-old boy. Accordingly, screening guidelines
recommend yearly or biannual abdominal MRI from six-
teen years of age and yearly abdominal ultrasound starting
at 8 years of age. The occurrence of RCC in a fifteen-years
old boy with a truncating germline VHL mutation high-
lights that renal cell carcinoma can be detected in patients
with nonsense VHL mutations younger than sixteen years
of age. Taken into account that abdominal MRI scans with
a higher resolution can detect RCC earlier than ultra-
sound, patients with nonsense mutations known to associ-
ate to RCC and early onset of the VHL disease [23] could
be considered for earlier MRI scans. In general, genetic
status might be considered to help tailoring individual
screening schedules in the future.
Conclusion
Genotype-phenotype correlation was analyzed and related
to the findings reported in previous publications. In our
study population we confirmed that the disruption of the
VHL protein integrity leading to the disregulation of HIF-
1alpha associate to type I phenotype. Accordingly, we also
showed that the proportion of non-deleterious mutations
is higher in type II than in type I missense mutations
among mutations reported in familial VHL cases. Here we
show the earliest occurrence of RCC reported in VHL dis-
ease so far and suggest individual tailoring of screening
schedule based on molecular genetic status. Clinical and
genetic data presented in our study can help the routine
of genetic counseling and patient follow-up, as well as the
presymptomatic molecular genetic diagnostics and con-
tribute to a better understanding of genotype-phenotype
correlations.
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